ClinicalTrials.gg
CompletedNCT00448279Updated Oct 24, 2014Results posted

THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

A Phase 3 interventional study of trastuzumab and Chemotherapy in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 35 sites in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-24.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
198th of 366
58 · median 61
Started
2007
with 18 others
Phase 3
60 of 374
3 open now
Registered
93rd of 374
by date
Lead sponsor
31 of 374
Hoffmann-La Roche

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 198th largest by enrollment of the 366 interventional ones that give a count, is one of 19 that started in 2007, is one of 60 in phase 3, and was the 93rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This 2 arm study will compare the efficacy and safety of continuation or discontinuation of Herceptin treatment in combination with 2nd line chemotherapy, in patients with HER2 positive metastatic breast cancer whose condition has progressed on 1st line chemotherapy plus Herceptin. Patients will be randomized either to continue or discontinue Herceptin treatment (2mg/kg iv infusion weekly, or 6mg/kg iv infusion every 3 weeks) while receiving 2nd line chemotherapy of the investigator's choice. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female patients, >=18 years of age;
  • breast cancer;
  • overexpression (IHC 3+ and/or FISH positive);
  • disease progression during or after previous chemotherapy plus Herceptin;
  • scheduled to receive 2nd line chemotherapy.

Exclusion criteria

Exclusion Criteria:

  • incompatibility with previous Herceptin therapy;
  • pregnancy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Active comparator
    Chemotherapy Alone

    Chemotherapy, schedule and dose at the investigator's discretion.

    Drug: Chemotherapy

  • Experimental
    Chemotherapy, Trastuzumab

    Trastuzumab, at the investigator's discretion, either 2 milligrams per kilogram (mg/kg) intravenous (i.v.) every 7 days or 6 mg/kg i.v. every 3 weeks. Chemotherapy, schedule and dose at the investigator's discretion.

    Drug: trastuzumab · Drug: Chemotherapy

Interventions

  • 2mg/kg i.v. weekly, or 6mg/kg i.v. every 3 weeks

    Also known as: Herceptin

  • DrugChemotherapy

    Schedule and dose at the investigator's discretion

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) - Percentage of Participants With an Event

    PFS was defined as the time from randomization to the date of documented disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or the date of occurrence of a second primary cancer, or date of death from any cause, whichever comes first. Participants were censored at the last tumour evaluation.

    Time frame: Baseline (BL) and every 8 weeks thereafter

  2. Progression-Free Survival - Time to Event

    The median time from randomization to PFS event. Participants were censored at the last tumour evaluation.

    Time frame: BL and every 8 weeks thereafter

Secondary outcomes

  1. Overall Survival (OS) - Percentage of Participants With an Event

    OS was defined as the time from randomization to the date of death from any cause. Participants were censored at the last contact date at which the participant was known to be alive.

    Time frame: BL and every 8 weeks thereafter

  2. Overall Survival - Time to Event

    The median time from randomization to OS event. Participants were censored at the last contact date at which the participant was known to be alive.

    Time frame: BL and every 8 weeks thereafter

  3. Percentage of Participants by Best Overall Response (BOR)

    BOR was defined as the best objective response observed during the treatment period according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete response (CR): disappearance of all target lesions (TLs), with any pathological lymph nodes (whether target or non-target) having a reduction in short axis to less than 10 millimeters (mm). Partial response (PR): at least a 30 percent (%) decrease in the sum of diameters of TLs, taking as reference the BL sum diameters. Progressive disease (PD): at least a 20% increase in the sum of diameters of TLs, taking as a reference the smallest sum on study (this included the BL sum if that is the smallest on study). In addition to the relative increase in 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. Stable disease (SD) was defined as neither sufficient shrinkages to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: BL and every 8 weeks thereafter

  4. Percentage of Participants With a Best Overall Response of CR or PR

    BOR was defined as the best objective response observed during the treatment period according to RECIST version 1.1. CR: disappearance of all TLs, with any pathological lymph nodes (whether target or non-target) having a reduction in short axis to less than 10 mm. PR: at least a 30% decrease in the sum of diameters of TLs, taking as reference the BL sum diameters. PD: at least a 20% increase in the sum of diameters of TLs, taking as a reference the smallest sum on study (this included the BL sum if that is the smallest on study). In addition to the relative increase in 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. SD: neither sufficient shrinkages to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: BL and every 8 weeks thereafter

07

Results

Posted Oct 24, 2014

Participant flow

Participant flow — Overall Study
MilestoneChemotherapy AloneChemotherapy Plus (+) Trastuzumab
Started2929
Completed00
Not completed2929
Withdrew: Lost to follow-up22
Withdrew: Adverse event11
Withdrew: Disease progression1618
Withdrew: Withdrawal by subject43
Withdrew: Other64
Withdrew: Protocol violation01

Outcome measures

PrimaryProgression-Free Survival (PFS) - Percentage of Participants With an Event

PFS was defined as the time from randomization to the date of documented disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or the date of occurrence of a second primary cancer, or date of death from any cause, whichever comes first. Participants were censored at the last tumour evaluation.

Time frame:
Baseline (BL) and every 8 weeks thereafter
Reported as:
Number · percentage of participants
Progression-Free Survival (PFS) - Percentage of Participants With an Event
percentage of participantsChemotherapy AloneChemotherapy + Trastuzumab
Progression-Free Survival (PFS) - Percentage of Participants With an Event58.658.6
PrimaryProgression-Free Survival - Time to Event

The median time from randomization to PFS event. Participants were censored at the last tumour evaluation.

Time frame:
BL and every 8 weeks thereafter
Reported as:
Median · months
Progression-Free Survival - Time to Event
monthsChemotherapy AloneChemotherapy + Trastuzumab
Progression-Free Survival - Time to Event9.7 (5.5 to 18.9)9.4 (6.7 to 12.0)
SecondaryOverall Survival (OS) - Percentage of Participants With an Event

OS was defined as the time from randomization to the date of death from any cause. Participants were censored at the last contact date at which the participant was known to be alive.

Time frame:
BL and every 8 weeks thereafter
Reported as:
Number · percentage of participants
Overall Survival (OS) - Percentage of Participants With an Event
percentage of participantsChemotherapy AloneChemotherapy + Trastuzumab
Overall Survival (OS) - Percentage of Participants With an Event55.234.5
SecondaryOverall Survival - Time to Event

The median time from randomization to OS event. Participants were censored at the last contact date at which the participant was known to be alive.

Time frame:
BL and every 8 weeks thereafter
Reported as:
Median · months
Overall Survival - Time to Event
monthsChemotherapy AloneChemotherapy + Trastuzumab
Overall Survival - Time to Event19.1 (17.0 to 32.7)26.7 (14.0 to NA)
SecondaryPercentage of Participants by Best Overall Response (BOR)

BOR was defined as the best objective response observed during the treatment period according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete response (CR): disappearance of all target lesions (TLs), with any pathological lymph nodes (whether target or non-target) having a reduction in short axis to less than 10 millimeters (mm). Partial response (PR): at least a 30 percent (%) decrease in the sum of diameters of TLs, taking as reference the BL sum diameters. Progressive disease (PD): at least a 20% increase in the sum of diameters of TLs, taking as a reference the smallest sum on study (this included the BL sum if that is the smallest on study). In addition to the relative increase in 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. Stable disease (SD) was defined as neither sufficient shrinkages to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
BL and every 8 weeks thereafter
Reported as:
Number · percentage of participants
Percentage of Participants by Best Overall Response (BOR)
percentage of participantsChemotherapy AloneChemotherapy + Trastuzumab
CR010.3
PR27.620.7
SD24.124.1
PD17.213.8
Not Evaluated31.031.0
SecondaryPercentage of Participants With a Best Overall Response of CR or PR

BOR was defined as the best objective response observed during the treatment period according to RECIST version 1.1. CR: disappearance of all TLs, with any pathological lymph nodes (whether target or non-target) having a reduction in short axis to less than 10 mm. PR: at least a 30% decrease in the sum of diameters of TLs, taking as reference the BL sum diameters. PD: at least a 20% increase in the sum of diameters of TLs, taking as a reference the smallest sum on study (this included the BL sum if that is the smallest on study). In addition to the relative increase in 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. SD: neither sufficient shrinkages to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
BL and every 8 weeks thereafter
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Overall Response of CR or PR
percentage of participantsChemotherapy AloneChemotherapy + Trastuzumab
Percentage of Participants With a Best Overall Response of CR or PR27.6 (12.7 to 47.2)31.0 (15.3 to 50.8)

Adverse events

Collected over Adverse events (AEs) were recorded throughout the study. Drug-related serious AEs (SAEs) were collected, regardless of the time elapsed from last study treatment administration, even if the study had been closed.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Chemotherapy Alone—4/26 (15.4%)26/26 (100%)
Chemotherapy + Trastuzumab—1/28 (3.6%)26/28 (92.9%)
Most frequent serious events
Most frequent serious events
EventChemotherapy AloneChemotherapy + Trastuzumab
Febrile neutropeniaBlood and lymphatic system disorders1/260/28
General MalaiseGeneral disorders1/260/28
Acute renal failureRenal and urinary disorders1/260/28
Hospitalisation for intrapleuric chemotherapy and thoracentesisGeneral disorders1/260/28
Gastric volvulusGastrointestinal disorders0/261/28
Most frequent other events
Showing 10 of 61
Most frequent other events
EventChemotherapy AloneChemotherapy + Trastuzumab
NeutropeniaBlood and lymphatic system disorders16/269/28
LeukopeniaBlood and lymphatic system disorders13/267/28
Other - unspecifiedGeneral disorders8/269/28
NauseaGastrointestinal disorders8/261/28
AstheniaGeneral disorders7/261/28
AnemiaBlood and lymphatic system disorders5/261/28
FeverGeneral disorders5/263/28
VomitingGastrointestinal disorders5/261/28
DiarrheaGastrointestinal disorders2/265/28
AlopeciaSkin and subcutaneous tissue disorders3/263/28

Baseline characteristics

Intent-to-treat (ITT) population: all randomized participants.

Age, Continuous
Age, Continuous(years)Chemotherapy AloneChemotherapy + TrastuzumabTotal
Median59 (38 to 81)57 (39 to 82)58 (38 to 82)
Sex: Female, Male
Sex: Female, Male(Participants)Chemotherapy AloneChemotherapy + TrastuzumabTotal
Female292958
Male000
08

Study locations

35 sites
  • Avellino, 83100, Italy
  • Brescia, 25123, Italy
  • Candiolo, 10060, Italy
  • Carrara, 54033, Italy
  • Cona (Ferrara), 44124, Italy
  • Cosenza, 87100, Italy
  • Crotone - Kr, 88900, Italy
  • Fano, 61032, Italy
  • Firenze, 50139, Italy
  • Frattaminore, 80026, Italy
  • Genova, 16132, Italy
  • Lecce, 73100, Italy
  • Livorno, 57100, Italy
  • Mantova, 46100, Italy
  • Meldola, 47014, Italy
  • Napoli, 80131, Italy
  • Nocera Inferiore, 84014, Italy
  • Padova, 35128, Italy
  • Palermo, 90127, Italy
  • Pavia, 27100, Italy
  • Perugia, 06122, Italy
  • Pordenone, 33170, Italy
  • Potenza, 85100, Italy
  • Ragusa, 97100, Italy
  • Reggio Calabria, 89100, Italy
  • Rionero in Vulture, 85028, Italy
  • Roma, 00128, Italy
  • Roma, 00153, Italy
  • Salerno, 84131, Italy
  • San Giovanni Rotondo, 71013, Italy
  • Sassari, 07100, Italy
  • Sora, 03039, Italy
  • Taormina, 98030, Italy
  • Torino, 10125, Italy
  • Udine, 33100, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 4 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2007
First posted
Mar 16, 2007
Start
Apr 2007
Primary completionActual
Sep 2010
CompletionActual
Sep 2010
Results first posted
Oct 24, 2014
Last update
Oct 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00448279
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 16, 2007
Start date
Apr 2007
Primary completion
Sep 2010
Completion
Sep 2010
Results posted
Oct 24, 2014
Last update
Oct 24, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion